Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

ONCY

Oncolytics Biotech, Inc

Feb 13 • 04:00PM ET

1.06

+0.23 26.99 %

Healthcare • Biotechnology • Canada • NASD

Feb 13, 2:01 PMCluster of C-suite insider purchases ignited 24% intraday surge.

Peers: CRSP NTLA EDIT BLUE CLLS FATE IOVA ADAP PSTX TCRT

Index	-	P/E	-	EPS (ttm)	-0.28	Insider Own	1.86%	Shs Outstand	103.64M	Perf Week	19.65%
Market Cap	114.06M	Forward P/E	-	EPS next Y	-0.24	Insider Trans	24.14%	Shs Float	98.50M	Perf Month	0.95%
Enterprise Value	105.78M	PEG	-	EPS next Q	-0.06	Inst Own	2.91%	Short Float	3.89%	Perf Quarter	-6.61%
Income	-25.30M	P/S	-	EPS this Y	9.24%	Inst Trans	2.10%	Short Ratio	3.58	Perf Half Y	12.73%
Sales	0.00M	P/B	1325.00	EPS next Y	5.44%	ROA	-175.83%	Short Interest	3.83M	Perf YTD	21.28%
Book/sh	0.00	P/C	12.84	EPS next 5Y	7.08%	ROE	-745.66%	52W High	1.51 -29.80%	Perf Year	37.29%
Cash/sh	0.08	P/FCF	-	EPS past 3/5Y	8.27% 23.13%	ROIC	-5239.11%	52W Low	0.33 225.35%	Perf 3Y	-35.76%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	12.17% 10.88%	Perf 5Y	-60.45%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-4.93%	Oper. Margin	-	ATR (14)	0.10	Perf 10Y	-57.09%
Dividend Ex-Date	-	Quick Ratio	1.84	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	56.57	Recom	1.33
Dividend Gr. 3/5Y	- -	Current Ratio	1.84	EPS Q/Q	-13.66%	SMA20	6.03%	Beta	0.99	Target Price	5.50
Payout	-	Debt/Eq	7.50	Sales Q/Q	-	SMA50	7.88%	Rel Volume	4.34	Prev Close	0.83
Employees	28	LT Debt/Eq	5.00	Earnings	Nov 13 BMO	SMA200	10.15%	Avg Volume	1.07M	Price	1.06
IPO	Oct 05, 2001	Option/Short	No / No	EPS/Sales Surpr.	-61.39% -	Trades		Volume	4,646,464	Change	26.99%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-13-25	Initiated	Lake Street	Buy	$7
Oct-06-22	Initiated	Maxim Group	Buy	$3
Feb-17-21	Initiated	H.C. Wainwright	Buy	$15

Feb-05-26 09:35AM	$207B Market Shift: The Race for Fast Track Approval in Oncology (PR Newswire) -7.04%
08:55AM	Oncolytics receives FDA Fast Track Designation for pelareorep (TipRanks)
Feb-04-26 08:50AM	Oncolytics Biotech Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer (GlobeNewswire)
Jan-30-26 10:36AM	$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium (PR Newswire)
10:19AM	$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors (PR Newswire)
09:15AM	Loading…
Jan-28-26 09:15AM	Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment (PR Newswire)
Jan-27-26 10:50AM	Registration-Ready: How 2026's Clinical Leaders Are Beating Cancer Benchmarks (PR Newswire)
Jan-15-26 04:01PM	Oncolytics Biotech Announces Results of Special Meeting of Shareholders (GlobeNewswire) -7.33%
Jan-14-26 10:52AM	Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff (PR Newswire)
09:00AM	Oncolytics Biotech Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics (GlobeNewswire)
Jan-12-26 10:35AM	Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 (PR Newswire)
09:00AM	Oncolytics Biotech Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer (GlobeNewswire)
04:23AM	Oncolytics Biotech (ONCY) Leadership Strengthens As Pelareorep Advances (Insider Monkey)
Jan-10-26 09:05AM	Oncolytics outlines strategic rationale for proposal to change jurisdiction (TipRanks)
Jan-09-26 09:00AM	Oncolytics Biotech Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada (GlobeNewswire)
09:00AM	Loading…
Jan-08-26 09:00AM	Oncolytics Biotech Provides Update on Intellectual Property Strategy and Patent Filings (Business Wire)
Jan-07-26 10:32AM	How $594B in Precision Tech is Cracking the Metastatic Cancer Code (PR Newswire)
09:00AM	Oncolytics Biotech Expands Its Gastrointestinal Tumor Scientific Advisory Board with the Addition of Dr. Eileen OReilly, Dr. Neil Segal, and Dr. Van Morris (Business Wire)
Dec-31-25 07:25AM	Smart Oncology: 5 Stocks Chasing the $317B Prize (PR Newswire)
Dec-16-25 01:17PM	Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B (PR Newswire) +12.68%
09:00AM	Oncolytics Biotech Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer (Business Wire)
Dec-12-25 10:47AM	Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance (PR Newswire)
Dec-09-25 06:00PM	Oncolytics Biotech Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporation to Nevada (Business Wire)
Dec-03-25 09:35AM	Oncolytics Biotech (ONCY) Loses 8.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Nov-20-25 04:05PM	Oncolytics Biotech Provides Update on Special Meeting of Shareholders (Business Wire)
Nov-19-25 12:00PM	All You Need to Know About Oncolytics Biotech (ONCY) Rating Upgrade to Buy (Zacks)
09:00AM	Oncolytics Biotech Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer (Business Wire)
Nov-04-25 08:00AM	Oncolytics Biotech Establishes Gastrointestinal Tumor Scientific Advisory Board to Advance Pelareorep as a Platform Immunotherapy (Business Wire) -11.48%
Oct-28-25 07:30AM	Oncolytics Biotech Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care (PR Newswire)
Oct-20-25 09:00AM	Oncolytics Biotech Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada (PR Newswire)
08:30AM	Loading…
Sep-29-25 08:30AM	Oncolytics Biotech Announces Update for Potential First-Line Pancreatic Cancer Registration Study (PR Newswire) +9.30%
Sep-16-25 12:29PM	Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals (PR Newswire)
07:00AM	Oncolytics Biotech Provides Update on GOBLET Study Progress and U.S. Site Expansion (PR Newswire)
Sep-08-25 09:30AM	Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market (PR Newswire) +20.75%
07:00AM	Oncolytics Biotech Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions (PR Newswire)
Sep-02-25 09:30AM	Breakthrough Cancer Therapies Fuel Regulatory Momentum as Global Market Expands (PR Newswire) +10.58%
09:10AM	Oncolytics Biotech Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors (PR Newswire)
Aug-31-25 08:40AM	Large-cap biotech is a sector to watch for investors: Analysts (Yahoo Finance)
Aug-28-25 10:44AM	FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone (PR Newswire)
08:30AM	Oncolytics Biotech Announces Upcoming Investor Conferences in September (PR Newswire)
Aug-14-25 12:30PM	Biotech Stocks Rally as Oncology Market Targets $866B by 2034 (PR Newswire) -7.81%
12:22PM	Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment (PR Newswire)
Aug-11-25 04:55PM	Oncolytics Biotech Announces Voting Results from the Annual General Meeting of Shareholders (PR Newswire)
Aug-08-25 09:05AM	Oncolytics Biotech Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep (PR Newswire) -6.20%
09:00AM	Oncolytics Biotech Announces Voluntary Delisting from the Toronto Stock Exchange (PR Newswire)
Aug-05-25 08:30AM	Oncolytics Biotech Announces Upcoming Annual General Meeting and Second Quarter Financial Results (PR Newswire) +7.58%
Jul-29-25 03:46PM	Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments (PR Newswire) -6.42%
08:30AM	Oncolytics Biotech to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End (PR Newswire)
Jul-23-25 09:39AM	Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential (PR Newswire)
09:26AM	High-Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds (PR Newswire)
Jul-22-25 03:32PM	Oncolytics Biotech Regains Compliance with Nasdaq Trading Rules (PR Newswire)
Jul-16-25 06:51PM	Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities (PR Newswire) +10.62% +5.60%
08:30AM	Oncolytics Biotech Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types (PR Newswire)
Jul-10-25 09:20AM	Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up (PR Newswire) -7.08%
08:30AM	Oncolytics Biotech to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers (PR Newswire)
Jul-08-25 08:30AM	Oncolytics Biotech Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies (PR Newswire) +23.76%
Jun-30-25 11:02AM	Oncology Innovation Just Hit a Turning Point -- Here's What to Watch (PR Newswire)
07:00AM	Oncolytics Biotech Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy (PR Newswire)
Jun-26-25 11:44AM	The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough? (PR Newswire)
Jun-24-25 12:52PM	Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices (PR Newswire) +5.79%
Jun-20-25 09:21AM	With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology (PR Newswire) -6.74%
Jun-18-25 11:19AM	Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going (PR Newswire) +10.76%
Jun-12-25 10:00AM	As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming From Industry (PR Newswire)
09:00AM	After Major Oncology Conference, All Eyes Turn to Industry Innovation (PR Newswire)
Jun-11-25 07:00AM	Oncolytics Biotech Names New CEO to Accelerate Momentum in Immunotherapy Programs (PR Newswire) +34.10%
May-23-25 09:10AM	New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs (PR Newswire)
07:00AM	Oncolytics Biotech to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities (PR Newswire)
May-15-25 03:15AM	Oncolytics Biotech Inc (ONCY) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
May-14-25 04:01PM	Oncolytics Biotech Reports First Quarter Financial Results and Highlights Clinical Momentum (PR Newswire)
May-06-25 07:00AM	Oncolytics Biotech to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights (PR Newswire) -6.42%
May-01-25 11:04AM	New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty (PR Newswire)
Apr-24-25 07:00AM	Oncolytics Biotech to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action (PR Newswire)
Apr-14-25 10:15AM	With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz (PR Newswire) -5.28%
Apr-10-25 06:09PM	Oncolytics Biotech Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital (PR Newswire) +24.56%
07:00AM	Oncolytics Biotech and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers (PR Newswire)
Mar-08-25 07:33AM	Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge (PR Newswire)
02:03AM	Oncolytics Biotech Inc (ONCY) Q4 2024 Earnings Call Highlights: Promising Cancer Study Results ... (GuruFocus.com)
Mar-07-25 07:00AM	Oncolytics Biotech Reports Highlights and Financial Results for Q4 and Year-End 2024 (PR Newswire) -6.29%
Mar-05-25 09:35AM	Oncolytics Biotech (ONCY) Loses -9.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +13.52%
Feb-27-25 10:10AM	Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 (PR Newswire)
Feb-25-25 07:00AM	Oncolytics Biotech to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights (PR Newswire)
Feb-19-25 10:10AM	Investors Eye Biotech Sector as Cancer Therapy Market Surges (PR Newswire)
07:00AM	Oncolytics Biotech Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025 (PR Newswire)
Feb-18-25 07:00AM	Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer (PR Newswire)
Feb-14-25 05:15PM	Oncolytics Biotech Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency (PR Newswire)
Feb-07-25 09:24PM	Oncolytics Biotech Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence (PR Newswire)
Feb-05-25 12:00PM	Oncolytics Biotech (ONCY) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Jan-22-25 09:00AM	Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium (PR Newswire) +5.26%
07:00AM	Oncolytics Biotech to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium (PR Newswire)
Jan-16-25 11:17AM	German PEI approves enrolment in cohort 5 of Oncolytics pancreatic cancer trial (Clinical Trials Arena)
Jan-15-25 10:10AM	Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year (PR Newswire)
07:02AM	Regulatory Approval Clears Path for Oncolytics Biotech to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data (PR Newswire)
Dec-26-24 11:26AM	Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment (PR Newswire)
09:00AM	Achievements and Progress Heading into 2025 for Oncology Treatments and Therapies Fuel an Optimistic Outlook (GlobeNewswire)
Dec-23-24 10:49AM	How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options (PR Newswire) +9.00%
07:00AM	Oncolytics Biotech Highlights 2024 Achievements and Prepares for an Influential 2025 with Promising Breast and GI Cancer Data (PR Newswire)
Dec-20-24 12:52PM	Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses (PR Newswire) -6.36%
Dec-18-24 11:12AM	Cancer Care Disruptions Highlight Growing Demand for Innovative Oncology Treatments (PR Newswire)
08:45AM	Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic and Anal Cancers (GlobeNewswire)
07:00AM	Oncolytics Biotech to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium (PR Newswire)

Oncolytics Biotech, Inc. engages in the provision of development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolation of the reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kelly Jared	Chief Executive Officer	Feb 12 '26	Buy	0.84	29,500	24,839	109,000	Feb 13 07:00 AM
Kelly Jared	Chief Executive Officer	Feb 11 '26	Buy	0.84	5,600	4,682	79,500	Feb 13 07:00 AM
Look Kirk	Chief Financial Officer	Feb 12 '26	Buy	0.84	12,000	10,104	287,515	Feb 13 07:00 AM
Pisano Wayne	Director	Feb 12 '26	Buy	0.84	30,000	25,338	492,414	Feb 13 07:00 AM
Heineman Thomas Charles	Chief Medical Officer	Feb 12 '26	Buy	0.83	12,132	10,033	282,818	Feb 13 07:00 AM
Brown Deborah Margaret	Director	Feb 12 '26	Buy	0.85	25,000	21,240	109,851	Feb 13 07:00 AM
Hagerman Allison	VP, Product Development	Feb 12 '26	Buy	0.83	10,000	8,298	115,059	Feb 13 07:00 AM
Seizinger Bernd R.	Director	Feb 11 '26	Buy	0.83	60,000	49,590	526,991	Feb 13 07:00 AM
Seizinger Bernd R.	Director	Feb 12 '26	Buy	0.85	40,000	33,864	566,991	Feb 13 07:00 AM
Aromando Andrew	Chief Business Officer	Feb 11 '26	Buy	0.86	29,600	25,418	55,100	Feb 13 07:00 AM
Andrews Patricia S	Director	Feb 12 '26	Buy	0.86	35,400	30,292	78,128	Feb 13 07:00 AM
Seizinger Bernd R.	Director	Jan 16 '26	Buy	1.04	100,000	103,770	466,991	Jan 20 04:30 PM

Open in Screener

APRE

Aprea Therapeutics Inc

Feb 13 • 04:00PM ET

0.6094

+0.0167 2.82 %

Healthcare • Biotechnology • USA • NASD

APRE Aprea Therapeutics Inc daily Stock Chart

Peers: BMY MRK PFE GILD VRTX AMGN BIIB REGN NBIX INCY

| Held by: VXF

Index	-	P/E	-	EPS (ttm)	-2.14	Insider Own	20.46%	Shs Outstand	5.98M	Perf Week	-11.68%
Market Cap	4.26M	Forward P/E	-	EPS next Y	-1.18	Insider Trans	4.39%	Shs Float	5.56M	Perf Month	-32.29%
Enterprise Value	-8.73M	PEG	-	EPS next Q	-0.39	Inst Own	21.78%	Short Float	4.68%	Perf Quarter	-51.63%
Income	-13.04M	P/S	8.69	EPS this Y	15.32%	Inst Trans	-8.83%	Short Ratio	0.13	Perf Half Y	-63.94%
Sales	0.49M	P/B	0.33	EPS next Y	40.87%	ROA	-63.27%	Short Interest	0.26M	Perf YTD	-28.56%
Book/sh	1.83	P/C	0.31	EPS next 5Y	29.22%	ROE	-74.72%	52W High	3.71 -83.60%	Perf Year	-82.74%
Cash/sh	1.96	P/FCF	-	EPS past 3/5Y	59.30% 52.12%	ROIC	-112.01%	52W Low	0.55 11.20%	Perf 3Y	-93.57%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	95.55%	Volatility	12.58% 19.29%	Perf 5Y	-99.58%
Dividend TTM	-	EV/Sales	-17.82	EPS Y/Y TTM	23.87%	Oper. Margin	-2829.92%	ATR (14)	0.11	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.20	Sales Y/Y TTM	-62.75%	Profit Margin	-2670.56%	RSI (14)	35.83	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.20	EPS Q/Q	26.78%	SMA20	-16.48%	Beta	1.51	Target Price	5.33
Payout	-	Debt/Eq	0.00	Sales Q/Q	-99.48%	SMA50	-28.49%	Rel Volume	0.09	Prev Close	0.59
Employees	8	LT Debt/Eq	0.00	Earnings	Nov 12 BMO	SMA200	-56.56%	Avg Volume	2.02M	Price	0.61
IPO	Oct 03, 2019	Option/Short	No / Yes	EPS/Sales Surpr.	-38.24% -	Trades		Volume	182,854	Change	2.82%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-28-20	Downgrade	Robert W. Baird	Outperform → Neutral
Dec-16-20	Initiated	Berenberg	Buy	$37
Sep-29-20	Resumed	JP Morgan	Neutral	$25
Jun-22-20	Initiated	H.C. Wainwright	Neutral	$30
Apr-21-20	Initiated	Robert W. Baird	Outperform	$45
Oct-28-19	Initiated	RBC Capital Mkts	Outperform	$33
Oct-28-19	Initiated	Morgan Stanley	Equal-Weight	$23
Oct-28-19	Initiated	JP Morgan	Neutral	$23

Feb-12-26 08:30AM	Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth (GlobeNewswire)
Feb-04-26 08:30AM	Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor (GlobeNewswire)
Jan-29-26 08:27AM	Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan (GlobeNewswire) -22.78%
08:25AM	Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules (GlobeNewswire)
Jan-19-26 05:14AM	New Strong Sell Stocks for January 19th (Zacks)
04:21AM	Loading…
Jan-14-26 04:21AM	New Strong Sell Stocks for Jan. 14 (Zacks)
Dec-18-25 08:30AM	Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026 (GlobeNewswire)
Dec-09-25 08:30AM	Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -10.80%
Nov-12-25 08:30AM	Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update (GlobeNewswire)
Oct-24-25 08:30AM	Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051 (GlobeNewswire) -7.89%
Oct-15-25 08:00AM	Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies (GlobeNewswire)
Oct-14-25 08:00AM	Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Aug-28-25 08:30AM	Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-12-25 08:00AM	Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update (GlobeNewswire)
Jun-25-25 09:00AM	Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center (GlobeNewswire) +10.09%
08:00AM	Loading…
May-14-25 08:00AM	Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update (GlobeNewswire)
May-06-25 04:01PM	Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates (Business Wire)
Apr-17-25 07:00AM	Adicet Bio Appoints Michael Grissinger to the Board of Directors (Business Wire)
Apr-01-25 08:49AM	Aprea doses HPV+ HNSCC subject in cohort 5 of APR-1051 trial (Clinical Trials Arena) -5.88%
Mar-31-25 08:30AM	Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial (GlobeNewswire)
Mar-25-25 08:30AM	Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Mar-11-25 08:30AM	Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC) (GlobeNewswire) +9.87%
Feb-06-25 08:16AM	Aprea Therapeutics provides update on existing patent portfolio (TipRanks)
Feb-05-25 08:00AM	Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics (GlobeNewswire)
Dec-11-24 08:30AM	Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward (GlobeNewswire)
Nov-13-24 09:55AM	Here's Why Aprea Therapeutics (APRE) Could be Great Choice for a Bottom Fisher (Zacks)
Nov-07-24 09:20AM	Aprea Therapeutics, Inc. (APRE) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
08:00AM	Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Oct-24-24 08:40AM	Aprea Therapeutics presents preliminary results on APR-1051 (TipRanks)
Oct-23-24 08:30AM	Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics (GlobeNewswire) -6.70%
08:30AM	Loading…
Oct-14-24 08:30AM	Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit (GlobeNewswire)
Oct-10-24 07:03PM	Stonepine Capital Management, LLC Increases Stake in Aprea Therapeutics Inc (GuruFocus.com)
08:30AM	Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics (GlobeNewswire)
Oct-09-24 08:30AM	Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development (GlobeNewswire)
Sep-25-24 08:00AM	Aprea Therapeutics to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024 (GlobeNewswire)
Sep-20-24 08:35AM	Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing (GlobeNewswire) +7.19%
Sep-16-24 12:07PM	Life Sciences Virtual Investor Forum Agenda Announced for September 19th (GlobeNewswire)
Sep-12-24 08:30AM	Aprea Therapeutics to Present at the Life Sciences Investor Forum on September 19 (GlobeNewswire) +6.21%
Sep-09-24 05:15PM	UPDATE - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference (GlobeNewswire)
04:05PM	Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference (GlobeNewswire)
Aug-28-24 08:30AM	Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference (GlobeNewswire)
Aug-12-24 09:45AM	Aprea Therapeutics, Inc. (APRE) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
08:30AM	Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-17-24 08:00AM	Alltrna Announces Updates to Its Board of Directors (PR Newswire)
Jun-21-24 08:00AM	Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024 (GlobeNewswire)
Jun-17-24 08:30AM	Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051 (GlobeNewswire)
May-28-24 08:45AM	Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial (GlobeNewswire)
May-14-24 01:53PM	APRE Stock Earnings: Aprea Therapeutics Beats EPS for Q1 2024 (InvestorPlace) +5.37%
08:30AM	Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
May-13-24 04:01PM	Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-02-24 09:15AM	Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-10-24 12:00PM	Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024 (GlobeNewswire)
Mar-26-24 01:53PM	APRE Stock Earnings: Aprea Therapeutics Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
07:45AM	Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Mar-11-24 08:30AM	Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million (GlobeNewswire) -5.05%
08:29AM	Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers (GlobeNewswire)
Mar-05-24 04:45PM	Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024 (GlobeNewswire)
Feb-06-24 08:01AM	Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor (GlobeNewswire) +11.97%
Jan-30-24 08:00AM	Aprea Therapeutics to Present at DDR Inhibitors Summit 2024 (GlobeNewswire)
Jan-04-24 04:05PM	Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024 (GlobeNewswire)
Nov-09-23 04:05PM	Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire) -5.19%
Oct-24-23 08:00AM	Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways (GlobeNewswire)
Oct-16-23 08:30AM	Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio (GlobeNewswire)
Sep-19-23 08:00AM	Aprea Therapeutics Announces Two Posters at the Upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Sep-11-23 08:00AM	Aprea Announces Preclinical Data Supporting Highly Differentiated WEE1 Inhibitor, ATRN-1051, Relative To Other WEE1 Inhibitors (GlobeNewswire)
Sep-06-23 04:05PM	Aprea Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-24-23 07:30AM	Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairman (GlobeNewswire)
Aug-10-23 07:30AM	Aprea Therapeutics Reports Second Quarter 2023 Financial Results and Provides Update on Business Operations (GlobeNewswire)
Jun-14-23 08:00AM	Aprea Therapeutics to Present at Maxim Virtual Healthcare Conference (GlobeNewswire)
May-30-23 08:30AM	Aprea Therapeutics to Present at BIO International Convention (GlobeNewswire) +11.76%
May-15-23 04:05PM	Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business Operations (GlobeNewswire) -7.34% +6.20%
May-08-23 08:00AM	Aprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of Directors (GlobeNewswire)
Apr-24-23 09:55AM	Bears are Losing Control Over Aprea Therapeutics, Inc. (APRE), Here's Why It's a 'Buy' Now (Zacks)
Apr-04-23 12:00PM	All You Need to Know About Aprea Therapeutics, Inc. (APRE) Rating Upgrade to Buy (Zacks) -5.01%
Mar-30-23 04:05PM	Aprea Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Update on Business Operations (GlobeNewswire)
Mar-16-23 08:00AM	Aprea Therapeutics Announces Presentation of Preclinical Data on Pipeline Programs at the AACR 2023 Annual Meeting (GlobeNewswire)
Mar-07-23 08:00AM	Aprea Therapeutics to Present at Oppenheimers 33rd Annual Healthcare Conference (GlobeNewswire) -5.26%
Mar-01-23 04:05PM	Aprea Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Feb-27-23 04:05PM	Aprea Therapeutics Announces Closing of $5.5 Million Underwritten Public Offering of Common Stock (GlobeNewswire)
Feb-22-23 08:41PM	Aprea Therapeutics Announces Pricing of $5.5 Million Underwritten Public Offering of Common Stock (GlobeNewswire) -19.97%
04:05PM	Aprea Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Feb-15-23 08:00AM	Aprea Therapeutics Announces Phase II SBIR Award from the National Cancer Institute (NCI) (GlobeNewswire)
Feb-13-23 07:00AM	Aprea Therapeutics Announces One-for-Twenty Reverse Stock Split (GlobeNewswire)
Jan-30-23 08:00AM	Aprea Therapeutics Appoints John Hamill as Chief Financial Officer (GlobeNewswire)
Jan-19-23 08:00AM	Aprea Therapeutics to Participate in 6th Annual DNA Damage and Response (DDR) Inhibitors Summit (GlobeNewswire) -7.57%
Jan-12-23 09:56AM	Aprea (APRE) Rises on Advancing Lead Drug to Clinical Studies (Zacks)
Jan-11-23 08:00AM	Aprea Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of Oral ATR Inhibitor ATRN-119 for the Treatment of Advanced Solid Tumors (GlobeNewswire) +11.99%
Nov-09-22 04:15PM	Aprea Therapeutics Reports Third Quarter 2022 Financial Results and Provides Update on Business Operations (GlobeNewswire) -10.88%
Sep-22-22 06:00PM	Aprea Therapeutics Announces Poster Presentation at the 2022 Rivkin Center and American Association for Cancer (AACR) Virtual Ovarian Cancer Research Seminar Series (GlobeNewswire) -7.14%
Sep-08-22 08:00AM	Aprea Therapeutics to Participate in the 2022 H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-11-22 04:15PM	Aprea Therapeutics Reports Second Quarter 2022 Financial Results and Provides Update on Business Operations (GlobeNewswire)
Aug-02-22 08:00AM	Aprea Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Conference (GlobeNewswire)
May-19-22 06:30AM	The Petri Dish: Taiho acquires Cullinan cancer subsidiary in $405M deal (American City Business Journals)
May-16-22 09:21AM	Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports First Quarter 2022 Financial Results (GlobeNewswire) -19.09%
Mar-15-22 04:15PM	Aprea Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Update on Business Operations (GlobeNewswire) +5.45% +14.37%
Mar-02-22 04:41AM	Is Aprea Therapeutics (NASDAQ:APRE) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Jan-14-22 10:00AM	Aprea Therapeutics, Inc. (APRE) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Jan-06-22 08:00AM	Aprea Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 (GlobeNewswire)
Dec-14-21 08:00AM	Recap and Update of Positive Data from Three Presentations in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Presented at the 2021 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) -10.05%
Dec-13-21 08:00AM	Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML at the 2021 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) -10.85%

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. It is involved in the development and commercialization of novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman, Staffan Stromblad, Natalia Issaeva, Galina Selivanova, and Wen Jie Bao in 2002 and is headquartered in Doylestown, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gilad Oren	President/CEO	Jan 30 '26	Buy	0.89	28,100	25,009	373,720	Feb 02 04:08 PM
Hamill John P.	SrVP/CFO/Prin Fin & Acct Ofcr	Jan 30 '26	Buy	0.89	5,700	5,073	33,433	Feb 02 04:05 PM
Duey Marc	Director	Dec 10 '25	Buy	1.17	21,459	25,000	256,155	Dec 11 08:31 AM
Hamill John P.	SrVP/CFO/Prin Fin & Acct Ofcr	Dec 10 '25	Buy	1.17	5,000	5,825	27,733	Dec 11 08:31 AM
Gilad Oren	President/CEO	Apr 03 '25	Buy	1.84	5,500	10,110	345,620	Apr 04 07:30 AM

ONCY

Oncolytics Biotech, Inc

APRE

Aprea Therapeutics Inc

Upgrade your FINVIZ experience